Histone deacetylase 1 and Histone deacetylase 2 (HDAC1/HDAC2)

Histone deacetylase 1 (HDAC1) and histone deacetylase 2 (HDAC2) are highly homologous members of the class I HDAC family of enzymes, which function primarily as negative regulators of gene expression through removal of acetyl groups from lysine residues on histones and various non-histone proteins[1][2][7]. This deacetylation tightens chromatin structure and suppresses gene transcription, but HDAC1/2 also regulate protein function and stability through deacetylating non-histone targets[4]. HDAC1 and HDAC2 typically operate as part of multi-protein co-repressor complexes (e.g., Sin3, NuRD, CoREST, MiDAC) that target them to genomic loci[2][5]. They play essential roles in cell proliferation, differentiation, DNA methylation, cell cycle control, and apoptosis[1][3]. Dysregulation and overexpression of these enzymes have been implicated in a variety of cancers, as well as neurodevelopmental and neurodegenerative diseases[1][4]. Inhibition of HDAC1/HDAC2 is a clinically validated therapeutic approach, particularly in oncology, and several HDAC inhibitors targeting these enzymes have been approved or are in late-stage clinical trials[1][2].

Other names

HDAC1HDAC2

Inhibition of histone deacetylase enzymatic activity, leading to increased histone acetylation and derepression of silenced genes; Modulation of chromatin structure, resulting in altered gene expression (pro-apoptotic, anti-proliferative, cell differentiation)